PAREXEL's Chuck Stevens, VP, Comments on Key Trends at DIA
The theme for this year's DIA is "Invest in the Future" and to that end, I've seen three tracks that speak to that. One is rare disorders and there's a lot of drug development that's taking place in rare and orphan diseases. The second is a track in comparative effectiveness research and health economics and outcomes modeling. The third is in medical communications of trying to share the story of drugs to providers and patients in the marketplace. Themes related to those issues are how to take drugs that go through a regulatory approval process, regardless of where they are in the globe and then meet payer expectations to make sure that patient consumers can get access to therapy and those drugs then become commercially successful. PAREXEL is uniquely qualified to support our client throughout the development process because we look at the drug development process as a journey and we make it our mission to make sure that we provide strategic guidance that allows our client to be successful while going through the regulatory process and ultimately getting patients access to therapy which makes the product successful.